AI assistant
PTC THERAPEUTICS, INC. — Director's Dealing 2015
Jul 7, 2015
31046_dirs_2015-07-06_e93eb284-1459-40d5-a637-b15fd56bacdd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PTC THERAPEUTICS, INC. (PTCT)
CIK: 0001070081
Period of Report: 2015-07-06
Reporting Person: SOUTHWELL DAVID P (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-07-06 | Common Stock | M | 15000 | $10.85 | Acquired | 23604 | Direct |
| 2015-07-06 | Common Stock | S | 22904 | $47.50 | Disposed | 700 | Direct |
| 2015-07-06 | Common Stock | S | 700 | $48.22 | Disposed | 0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2015-07-06 | Stock Option (right to buy) | $10.85 | M | 15000 | Disposed | 2023-05-15 | Common Stock (15000) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (right to buy) | $51.00 | 2025-01-01 | Common Stock (12000) | 12000 | Direct |
| Stock Option (right to buy) | $27.05 | 2024-01-27 | Common Stock (10000) | 10000 | Direct |
| Stock Option (right to buy) | $218.4 | 2022-01-10 | Common Stock (110) | 110 | Direct |
| Stock Option (right to buy) | $490.8 | 2021-04-27 | Common Stock (110) | 110 | Direct |
| Stock Option (right to buy) | $1149.6 | 2020-02-02 | Common Stock (95) | 95 | Direct |
| Stock Option (right to buy) | $508.8 | 2019-10-07 | Common Stock (108) | 108 | Direct |
| Stock Option (right to buy) | $735.6 | 2018-01-25 | Common Stock (83) | 83 | Direct |
| Stock Option (right to buy) | $626.4 | 2017-04-18 | Common Stock (83) | 83 | Direct |
| Stock Option (right to buy) | $392.4 | 2016-03-01 | Common Stock (125) | 125 | Direct |
Footnotes
F1: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person for the primary purpose of diversification.
F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $47.13 to $48.09 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $48.16 to $48.27 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4: This option was granted on May 15, 2013 and vests over three years, with 8.33% of the shares underlying the option vested on August 15, 2013 and an additional 8.33% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter.
F5: Currently exercisable.